0001062993-24-009877.txt : 20240510 0001062993-24-009877.hdr.sgml : 20240510 20240510160436 ACCESSION NUMBER: 0001062993-24-009877 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240508 FILED AS OF DATE: 20240510 DATE AS OF CHANGE: 20240510 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Familiar Calderon Gerardo CENTRAL INDEX KEY: 0001971603 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36794 FILM NUMBER: 24934732 MAIL ADDRESS: STREET 1: C/O THE CHEMOURS COMPANY STREET 2: 1007 MARKET STREET CITY: WILMINGTON STATE: DE ZIP: 19801 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Chemours Co CENTRAL INDEX KEY: 0001627223 STANDARD INDUSTRIAL CLASSIFICATION: CHEMICALS & ALLIED PRODUCTS [2800] ORGANIZATION NAME: 08 Industrial Applications and Services IRS NUMBER: 464845564 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 1007 MARKET STREET CITY: WILMINGTON STATE: DE ZIP: 19801 BUSINESS PHONE: 302 773 1000 MAIL ADDRESS: STREET 1: 1007 MARKET STREET CITY: WILMINGTON STATE: DE ZIP: 19801 FORMER COMPANY: FORMER CONFORMED NAME: Chemours Company, LLC DATE OF NAME CHANGE: 20141205 4 1 form4.xml STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES X0508 4 2024-05-08 0001627223 Chemours Co CC 0001971603 Familiar Calderon Gerardo C/O THE CHEMOURS COMPANY 1007 MARKET STREET WILMINGTON DE 19899 0 1 0 0 Pres Advanced Performance Mat 0 Common Stock 2024-05-08 4 A 0 5909 0.00 A 23727.8847 D Stock Option (Right to Buy) 27.50 2024-05-08 4 A 0 15807 0.00 A 2034-05-08 Common Stock 15807 15807 D Performance Stock Option (Right to Buy) 30.25 2024-05-08 4 A 0 16439 0.00 A 2034-05-08 Common Stock 16439 16439 D Restricted Stock Unit (RSU) award scheduled to vest in three equal annual installments beginning on March 1, 2025. Includes directly owned shares, restricted stock units and dividend equivalent units. These options are scheduled to vest in three equal annual installments beginning on May 8, 2025. Represents a 10 percent premium above the closing price of the Company common stock on the date of grant. /s/ Nicole Perez Lengel, Attorney-in-Fact 2024-05-10